Overview

Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

Status:
ENROLLING_BY_INVITATION

Trial end date:
2025-10-01

Target enrollment:

Participant gender:

Summary

RACEMATE is a phase 2b, multicentre, randomised, double-blinded, placebo-controlled study designed to explore the efficacy and mechanism of action of tezepelumab in adults with eosinophilic granulomatosis with polyangiitis (EGPA).

Phase:

PHASE2

Details

Lead Sponsor:

Imperial College London

Collaborator:

AstraZeneca

Treatments:

tezepelumab